Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- G&G to Develop Overseas Business in Earnest
August 31, 2009
- Allopurinol + Uralyt Combination Useful for Management of MetS
August 31, 2009
- SSP to Place Top Priority on Operating Profit Rate
August 31, 2009
- R&D NEWS IN BRIEF
August 31, 2009
- REGULATORY NEWS IN BRIEF
August 31, 2009
- Everolimus Approved in EU: Novartis
August 31, 2009
- Japan, China, South Korea Start Working-Level Regulatory Consultations
August 31, 2009
- Korosho to Promote Sharing of Know-how to Promote Use of Generics
August 31, 2009
- Sampling Tests Show Problems with Only 2 of 876 Products
August 31, 2009
- R&D NEWS IN BRIEF
August 24, 2009
- Cravit Tab 500 mg Prevents Emergence of Resistant Organisms: Daiichi Sankyo
August 24, 2009
- REGULATORY NEWS IN BRIEF
August 24, 2009
- Kowa's Livalo Approved in US
August 24, 2009
- Industry Will Refrain from Developing Suspicious Combination Drugs: Mr Hasegawa
August 24, 2009
- Decision on Drug Pricing System May Be Withheld until Budget Formation
August 24, 2009
- No Consensus Reached on NHI Drug Pricing System Reform at Chuikyo Meeting
August 24, 2009
- BUSINESS NEWS IN BRIEF
August 24, 2009
- Wholesalers Should Increase Profits by Offering Value through MSs: Mr Bessho
August 24, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 24, 2009
- Wholesalers' Gross Profit Rate Down to 7.09%
August 24, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…